FOXL2 and neoplasm: Mice receiving the combination of vaccine and anti–PD-L1 suppressed tumor progression (Figure 7C) (FoxL2-TT plus anti–PD-L1 vs. FoxL2-TT, P = 0.0042) and improved mice survival compared with vaccination (P < 0.007) or anti–PD-L1 (P < 0.001) monotherapies (Figure 7D).